Search

Author/Creator Gane, E.

12. Responses are durable for up to 5 years after completion of peginterferon alfa‐2a treatment in hepatitis B e antigen‐positive patients. Issue 9 (9th March 2018)

Authors:
Chuang, W.‐L.; Jia, J.; Chan, H. L. Y.; Han, K.‐H.; Tanwandee, T.; Tan, D.; Chen, X.; Gane, E.; Piratvisuth, T.; Chen, L.; Xie, Q.; Sung, J. J.‐Y.; Messinger, D.; Wat, C.; Bakalos, G.; Liaw, Y. F.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 47:Issue 9(2018)
Page Start:
1306
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. Issue 10 (8th May 2018)

Authors:
Martinello, M.; Bhagani, S.; Gane, E.; Orkin, C.; Cooke, G.; Dore, G. J.; Petoumenos, K.; Applegate, T. L.; Tu, E.; Marks, P.; Pagani, N.; Grebely, J.; Nelson, M.; Matthews, G. V.
Journal:
Journal of viral hepatitis
Issue:
Volume 25:Issue 10(2018)
Page Start:
1180
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2. (January 2015)

Authors:
Gane, E.; Kershenobich, D.; Seguin‐Devaux, C.; Kristian, P.; Aho, I.; Dalgard, O.; Shestakova, I.; Nymadawa, P.; Blach, S.; Acharya, S.; Anand, A. C.; Andersson, M. I.; Arendt, V.; Arkkila, P.; Baatarkhuu, O.; Barclay, K.; Ben‐Ari, Z.; Bergin, C.; Bessone, F.; Blokhina, N.
Journal:
Journal of viral hepatitis
Issue:
Volume 22(2015)Supplement 1
Page Start:
46
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2. (January 2015)

Authors:
Hatzakis, A.; Chulanov, V.; Gadano, A. C.; Bergin, C.; Ben‐Ari, Z.; Mossong, J.; Schréter, I.; Baatarkhuu, O.; Acharya, S.; Aho, I.; Anand, A. C.; Andersson, M. I.; Arendt, V.; Arkkila, P.; Barclay, K.; Bessone, F.; Blach, S.; Blokhina, N.; Brunton, C. R.; Choudhuri, G.
Journal:
Journal of viral hepatitis
Issue:
Volume 22(2015)Supplement 1
Page Start:
26
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. Issue 4 (9th December 2016)

Authors:
Alqahtani, S.; Ozaras, R.; Isakov, V.; Wyles, D.; Ferenci, P.; Feld, J. J.; Calinas, F.; Gschwantler, M.; Gane, E.; Crawford, D.; Jacobson, I. M.; Dumas, E. O.; King, M.; Sulkowski, M.
Journal:
Journal of viral hepatitis
Issue:
Volume 24:Issue 4(2017)
Page Start:
280
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

17. Toll‐IL1 receptor‐mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated‐IFN in HBeAg‐positive CHB patients. Issue 3 (5th October 2015)

Authors:
Visvanathan, K.; Lang, T.; Ryan, K.; Wilson, R.; Skinner, N. A.; Thompson, A. J. V.; Ahn, S. H.; Weilert, F.; Abbott, W.; Gane, E.; Colledge, D.; Li, K.; Locarnini, S.; Mansell, A.; Revill, P. A.
Journal:
Journal of viral hepatitis
Issue:
Volume 23:Issue 3(2016)
Page Start:
170
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗